Morillas, Rosa
Universitat Autònoma de Barcelona · Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol · Hospital Universitari Germans Trias i Pujol
6 papers on CoChatORCID 0000-0001-9117-5049
Most cited papers
- Verified
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial
Villanueva, C., Albillos, A., Genescà, J., Garcia-Pagan, J. C., Calleja, J. L., Aracil, C., Bañares, R., Morillas, R. M., Poca, M., Peñas, B., et al. (2019) · The Lancet
Liver Disease and TransplantationHeart Failure Treatment and Management
Cited by 711
- Verified
Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis
Abraldes, J. G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., Rodriguez, M., Castellote, J., García-Pagán, J. C., Torres, F., et al. (2016) · Gastroenterology
Liver Disease and TransplantationGastrointestinal Bleeding Diagnosis and Treatment
Cited by 339
- Verified
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis
Berzigotti, A., Garcia-Tsao, G., Bosch, J., Grace, N. D., Burroughs, A. K., Morillas, R., Escorsell, A., Garcia-Pagan, J. C., Patch, D., Matloff, D. S., et al. (2011) · Hepatology
Liver Disease and TransplantationLiver Disease Diagnosis and Treatment
Cited by 325
- Verified
Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid
Gomez, E., Garcia Buey, L., Molina, E., Casado, M., Conde, I., Berenguer, M., Jorquera, F., Simón, M., Olveira, A., Hernández‐Guerra, M., et al. (2021) · Alimentary Pharmacology & Therapeutics
Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments
Cited by 41
- Verified
Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study
Julián, M. T., Ballesta, S., Pera, G., Pérez-Montes de Oca, A., Soldevila, B., Caballería, L., Morillas, R., Expósito, C., Martínez–Escudé, A., Puig-Domingo, M., et al. (2023) · Frontiers in Endocrinology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 30
- Verified
Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy
Ampuero, J., Lucena, A., Berenguer, M., Hernández-Guerra, M., Molina, E., Gómez-Camarero, J., Valdivia, C., Gómez, E., Casado, M., Álvarez-Navascuez, C., et al. (2024) · Hepatology
Liver Diseases and ImmunityLiver Disease and Transplantation
Cited by 17
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free